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Abstract: Atypical lesions of a presumably idiopathic inflammatory demyelinating 
origin present quite  variably and may pose diagnostic problems. The subsequent 
clinical course is also uncertain. We therefore wanted to clarify if atypical idiopathic 
inflammatory demyelinating lesions (AIIDLs) can be classified according to previously 
suggested radiologic characteristics and how this classification relates to prognosis.  
Searching the databases of eight tertiary referral centres we identified 90 adult 
patients (61 women, 29 men; mean age 34 years) with ≥1 AIIDL. We collected their 
demographic, clinical and MRI data and obtained follow-up (FU) information on 77 of 
these patients over a mean duration of 4 years. AIIDLs presented as a single lesion 
in 72 (80%) patients and exhibited an infiltrative (n=35), megacystic (n=16), Baló 
(n=10) or ring-like (n=16) lesion appearance in 77 (86%) patients. Additional MS-
typical lesions existed in 48 (53%) patients. During FU a further clinical attack 
occurred rarely (23 -35% of patients) except for patients with ring-like AIIDLs (62%). 
Further attacks were also significantly more often in patients with coexisting MS-
typical lesions (41% vs. 10%, p < 0.005). New AIIDLs developed in 6 (7%), and new 
MS-typical lesions in 29 (42%) patients. Our findings confirm the previously reported 
subtypes of AIIDLs. Most types confer a relatively low risk of further clinical attacks, 
except for ring-like lesions and the combination with MS-typical lesions. 
 
Key words: atypical lesions, multiple sclerosis, MRI, prognosis, tumefactive lesions
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4 
Introduction  
Multiple sclerosis (MS) is the most frequent idiopathic inflammatory demyelinating 
disorder of the brain and has been associated with a quite characteristic lesion 
appearance on magnetic resonance imaging (MRI) (1, 2). Rarely patients also 
present with uncommon or atypical lesions for which – nevertheless - an idiopathic 
inflammatory origin is presumed (3). These lesions may occur as a singular event, or 
at onset or during the course of a relapsing-remitting disease which suggests some 
relation with “classical” MS. The frequency and intensity of this relation is not yet fully 
clear, however. To acknowledge the absence of more exact pathophysiologic 
insights and to avoid a-priori classification we therefore have suggested the rather 
neutral term atypical idiopathic inflammatory demyelinating lesions (AIIDLs) (4). 
Some of these lesions are commonly referred to as tumefactive lesions (5). Others 
have been associated with presumably severe “MS variants” like Schilder’s, 
Marburg’s or Baló’s diseases (6) . Except for Baló’s disease, however, these 
“variants” do not have a specific image appearance  (7) which is prohibitive when 
attempting to derive prognostic implications.  
AIIDLs also often pose a diagnostic problem by mimicking tumours or infectious 
inflammatory processes including abscesses. Furthermore their size and appearance 
tend to imply significant damage to the brain with severe functional deficits, although 
this has not been substantiated. Thus AIIDLs have received attention both in the 
pathologic and imaging literature but this has been limited mostly to individual case 
reports or small patient series. As a consequence no commonly agreed classification 
of AIIDLs has been produced, and their prognostic implications have remained 
unclear.  
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In a first step, we reviewed the literature and proposed an MRI classification based 
on specific morphologic characteristics of AIIDLs (4). These appeared to cluster into 
four subtypes, i.e. infiltrative, megacystic, Baló-like, and ring-like lesions, with only 
the latter being quite frequent in “classical” MS. While this has expanded the notion 
of MRI features which may be associated with an idiopathic inflammatory disorder – 
an important aspect for differential diagnostic considerations - we could not derive 
useful information on the subsequent disease course. This was due to limited clinical 
information and follow up, and reporting bias was a potentially important limitation. 
We, therefore, undertook a careful retrospective review of patients with AIIDLs, who 
had been observed and followed in centres of the MAGNIMS (Magnetic Resonance 
Network in MS) network in order to investigate how the occurrence of such lesions 
and of AIIDL subtypes relates to patients’ prognosis and an MS like course of the 
disease. In this effort we also wanted to test the applicability of suggested MRI 
classification for the description of AIIDLs. 
 
Methods 
Patient cohort 
We searched the databases of six centres of the MAGNIMS group and of two 
collaborating MS centres in Brazil and Mexico for patients with ≥1 atypical lesion on 
MRI. Patients had to be ≥18 years and the idiopathic inflammatory demyelinating 
aetiology of the lesion had to be confirmed by comprehensive diagnostic work-up 
including long-term follow-up in most cases.   
 
Clinical and MRI data 
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Patients’ charts and follow-up documentation were systematically reviewed at the 
individual centres using a standardised questionnaire. Special attention was given to 
the mode of clinical presentation, the course of disease including previous and 
further relapses, and patients’ disability as measured by the Expanded Disability 
Status Scale (EDSS) score (8). 
MRIs were reviewed centrally for number and type of AIIDLs following proposed 
classification (4) (table 1, figure 1), unaware of the clinical data. We also recorded the 
additional presence of MS-typical lesions and of contrast enhancement. Follow-up 
scans were interpreted in a similar manner, first separately and then in a side-by-side 
comparison with preceding investigations. Table 2 lists the number, age, gender, and 
types of AIIDLs identified in the participating centres.  
 
Statistical analysis 
Categorical variables were tested by Pearson’s chi square test or by 2x2 Fisher’s 
exact test in case of contingency tables containing less than five cases. Normally 
distributed continuous variables were compared using student’s t test. The level of 
significance was set at p<0.05.  
 
Results 
We identified a total of 90 patients (61 women, 29 men) with at least one AIIDL. Their 
age ranged from 18 to 64 years (mean 34 years). The infiltrative lesion type was 
observed most frequently (n=35) followed by ring-like (n=16), megacystic (n=16), and 
Baló-like (n=10) lesions (table 2). In 13 patients, imaging characteristics were mixed 
or not clearly attributable to one of the a priori defined lesion types. For the sake of 
comparison these were included as “other” in the analysis. The distribution of AIIDL 
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subtypes was quite uniform throughout the participating centres, except for a rather 
high number of megacystic lesions seen in patients contributed by the Sao Paulo 
center. Likewise patients’ mean age and gender distribution was quite comparable 
between centres.   
AIIDL associated symptoms constituted the first clinical attack in 70 (78%) patients. 
Table 3 shows the clinical presentations according to AIIDL subtypes. Motor and 
multifocal symptoms dominated. A single AIIDL was seen in 72 patients, while the 
remaining 18 patients showed two or more AIIDLs.  
The overall prevalence of additional MS-typical lesions was 53% (48 of 90 patients). 
Considering only patients showing an AIIDL together with a first attack the 
prevalence of lesions suggestive of MS was 44% (31 of 70 patients). In contrast, 
85% (17 of 20) patients with a previous attack exhibited MS-typical lesions in addition 
to the AIIDL (table 3). In patients with Baló-like lesions, 83% showed marked clinical 
improvement from the initial attack or fully recovered, whereas only 23% of patients 
with infiltrative lesions had a good clinical outcome (EDSS  1.0). In the other AIIDL 
subgroups good recovery was found in 45 % with megacystic and 49% with ring-like 
lesion appearance.  
Clinical follow-up was available from a total of 77 patients. The duration of follow-up 
ranged from 0.5 to 8 years (table 4). Two thirds or more of the patients experienced 
no further attack within the observational period, except for the group with ring-like 
AIIDLs who had further attacks in 62% of the followed patients. The EDSS at last 
follow-up ranged between 1.5 and 3.5 in the subgroups. A follow-up MRI was 
obtained in 69 patients. A further AIIDL developed only rarely. Interestingly, this 
lesion was different in appearance from the initial lesion type in four of six instances. 
On the other hand, new MS-typical lesions developed in 29 (42%) patients. 
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To investigate the role of coexisting MS typical lesions on a patient’s prognosis we 
looked separately at the groups of patients with and without such lesions at 
presentation with an AIIDL. As can be seen from table 5, new MS typical lesions 
developed in both subgroups but with a higher frequency in patients who had such 
lesions already at onset (52.6 % vs 29.0 %; p<0.01). Further attacks were also 
significantly more frequent in patients with MS typical lesions at presentation with an 
AIIDL (41.3% vs. 9.6%; p<0.005).   
 
Discussion 
Our study on patients with AIIDLs who were seen in tertiary referral centres 
addresses several important aspects. The majority of AIIDLs presented with one of 
the four appearances as suggested in our review of the literature (4). This is also 
supported by the quite similar distribution of AIIDL subtypes seen within the 
participating centres. In the present series we found a higher number of lesions of the 
infiltrative type as would have been expected from our review, but clearly a more 
rigorous and widespread collection of AIIDL cases would be needed to define the 
exact proportion and distribution of AIIDL subtypes. Noteworthy, some lesions could 
not be classified into any of the four subtypes. This was mostly because of a mixture 
of morphologic features or because AIIDLs did not completely meet the predefined 
classification characteristics at the time of the MRI examination.  
Regarding lesion occurrence it is of interest that AIIDLs were associated with a first 
clinical attack in most instances. Otherwise more than half of the patients also 
showed MS-typical lesions on their MRI scans of the brain. This is quite comparable 
to the experience in the series of Lucchinetti et al. (5) Multiple lesions were present in 
70% of their series and 46% fulfilled the Barkhof criteria prior to biopsy.  
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Our follow-up data also indicate that the appearance of any of the AIIDL subtypes, 
including non-classifiable AIIDLs, need not indicate a highly active relapsing course 
of the disease. In fact the rate of further relapses was rather low in all subtypes and 
ranged from 23 to 35%, with a higher frequency of 62% only in patients presenting 
with ring-like lesions. This is not unexpected as ring-like lesions are also frequently 
seen during the course of patients with a firm diagnosis of MS (9). Furthermore some 
difference in the length of follow-up between AIIDL subgroups has to be considered 
when interpreting these data. Importantly, further relapses developed primarily in 
those individuals with coexisting MS typical lesions at presentation with an AIIDL and 
thus these appear to be an indicator regarding further clinical activity. Interestingly 
this is similar to the observation in patients with a clinically isolated syndrome in 
general who have an increased likelyhood for ongoing disease in the presence of 
other MS-typical lesions (10). 
Overall the course of the disease was not specifically active in patients whose first 
clinical symptoms were caused by an AIIDL. The sometimes quite extensive lesions 
themselves, however, caused quite profound deficits in some instances although the 
recovery was good in the majority of patients. This resulted in a wide range of the 
EDSS at onset and also explains the rather high mean EDSS at last follow-up found 
in all subtypes considering the short-term disease duration. Presentation with an 
AIIDL thus does not appear to predict a bad long-term prognosis. This is in line with 
other recent reports of series on different subtypes of AIIDLs (11, 12) and provides 
useful information regarding patient counselling. Yet other investigators have made 
different observations (13).  Ethnicity and age are among the various factors that may 
account for this. Thus we did not include children in our series as they are known to 
more often present with quite extensive and diagnostically challenging immune-
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mediated lesions of the CNS (14). Furthermore this diversity in findings may come 
from differences in AIIDLs themselves which is not sufficiently reflected by the term 
“tumefactive” alone. We therefore suggest a more detailed classification of AIIDLs 
such as used in present analysis. 
On follow-up MRI there was a high likelihood for the appearance of new MS-typical 
lesions when present already at the initial exam. Such lesions developed in more 
than half of those patients and in all AIIDL subtypes. In contrast, new lesion 
development was seen in only 28% of patients  with no MS-typical lesions at 
baseline. The rate of further AIIDLs was low. They developed in only six of the 77 
patients and in three instances had a different lesion characteristic than before.  
Unfortunately, our study does not provide further and more firm information regarding 
therapy. For treatment of the acute attack, high-dose steroids were used in most 
instances, partly with a late response (15). Plasmapheresis was used in some cases. 
If and to what extent long-term immunomodulatory strategies were effective or 
differed in efficacy because of the presence of an AIIDL cannot be answered from 
our series. Only half of the patients were on immunomodulatory treatment and the 
rate of further attacks was low with or without such treatment. Another limitation 
stems from the inability to systematically examine the possible contribution of more 
advanced or other imaging techniques to the differential diagnosis of AIIDLs. Several 
suggestive features on diffusion-weighted imaging, perfusion-weighted imaging and 
magnetic resonance spectroscopy, but also cerebral angiography and positron 
emission tomography have been reported in individual series and would need 
confirmation  (7, 16-20). Finally we cannot exclude that despite careful search in the 
individual data banks some cases with AIIDLs were missed due to the retrospective 
nature of data collection which also precluded more homogenous follow-up 
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information. This may also have been the reason for the relatively low rate of ring-like 
lesions as many of those probably have not been considered AIIDLs anymore (9). 
In conclusion, our findings confirm the occurrence of predominantly four 
characteristic types of AIIDLs.  These lesion patterns should be considered in the 
differential diagnostic work-up of patients over a wide age range. The oldest of our 
patients with an AIIDL was 64 years old. In addition, there also exists a smaller 
number of AIIDLs not meeting these characteristics with similar implications. The 
concomitant presence of MS-typical lesions is an important hint for differential 
diagnostic clarification and such lesions should be actively searched for to avoid 
unnecessary biopsies. More than half of individuals who were available for follow-up 
remained free of further attacks over a mean of four years. Regarding prognostic 
implications there appears to be no great difference between AIIDL subtypes except 
for ring-like AIIDLs which are already an accepted finding within the spectrum of 
classical MS lesions. The likelihood of having or developing MS appears to be quite 
closely linked to the presence (higher likelihood of MS) or absence (lower likelihood 
of MS) of additional clinically silent MRI lesions typical for demyelination. 
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Table 1: Imaging characteristics of subtypes of atypical idiopathic inflammatory 
demyelinating lesiond (AIIDLs) (according to (4) 
 
 
 
AIIDL subtypes Imaging appearance  
infiltrative Large-ill defined areas of T2 abnormality with no or 
inhomogenous uptake of contrast material 
megacystic Large (≥ 3 cm in diameter) cyst like lesions often expanding 
along the cortical ribbon with incomplete rim of contrast 
enhancement 
Baló like Lesions with multiple concentric rings or a pattern of 
alternating bands of signal intensity (≥ 2 alternations) on any 
sequence 
Ring -like Round (≥ 2 cm in diameter) lesions with ring-like 
enhancement surrounded by an ill-defined zone of T2 
hyperintensity suggestive of edema 
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Table 2: Participating centres with demographics and atypical idiopathic inflammatory demyelinating lesions (AIIDL) subtypes of 
identified patients  
 
 Number of 
patients 
Mean age 
(range) 
Sex AIIDL subtypes 
   F M Infiltrative Ring-like Megacystic Baló-like other 
Barcelona 13 37.8 (22-62) 9 4 7 0 3 2 1 
Basel 2 22.0 (18-26) 2 0 2 0 0 0 0 
Copenhagen 7 34.4 (19-53) 5 2 3 2 1 1 0 
Graz 16 33.1 (24-53) 10 6 7 5 0 2 2 
London 8 40.1 (25-52) 5 3 3 2 1 0 2 
Mexico City 3 28.3 (19-36) 3 0 2 0 0 1 0 
Milan 13 36.2 (20-64) 8 5 5 1 1 1 5 
Sao Paulo 28 34.3 (18-58) 19 9 6 6 10 3 3 
Total 90 34.0 (18-64) 61 29 35 16 16 10 13 
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Table 3: Findings at presentation with an atypical idiopathic inflammatory demyelinating lesions (AIIDL) 
 
  Infiltrative 
(n=35) 
Megacystic 
(n=16) 
Baló-like 
(n=10) 
Ring-like 
(n=16) 
Other  
(n=13) 
Demographics      
Age in years, mean (range) 33.9 (18-55) 42.8 (19-64) 32.5 (19-62) 32.8 (18-51) 32.8 (26-39) 
Gender (female / male) 24 / 11 10 / 6 8 / 2 10 / 6 9 / 4 
Clinical findings      
First attack, n (%) 29 (82.8) 11 (68.7) 9 (90) 11 (68.7) 10 (77) 
Presenting symptoms      
   Optic neuritis (%) 1 (2.8) 0 0 0 0 
   Motor (%) 8 (22.9) 5 (31.3) 4 (40) 6 (37.5) 4 (30.8) 
  Sensory (%) 5 (14.3) 6 (37.5) 3 (30) 3 (18.8) 2 (15.4) 
  Brainstem (%) 3 (8.6) 0 0 2 (12.5) 0 
  Multifocal (%) 11 (31.4) 1 (6.2) 3 (30) 5 (31.2) 7 (53.8) 
  Other (%) 7 (20.0) 4 (25.0) 0 0 0 
MRI findings      
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1 AIIDL (with first attack) 31 (27) 12 (8) 7(6) 12(8) 10(2) 
>2 AIIDLs (with first attack) 4 (2) 4 (3) 3(3) 4(3) 3(1) 
presence of MS-typical lesions, all (%) 15 (42.9) 8 (50) 6 (60) 11 (68.7) 8 (61.5) 
    patients without previous attacks (%) 10 / 29 (34.5) 3 / 11 (27.3) 5 / 9 (55.6) 7 /11 (63.6) 6 / 10 (60.0) 
    patients with previous attacks (%) 5 / 6 (83.3) 5 / 5 (100) 1 / 1 (100) 4 / 5 (80.0) 2 / 3 (66.7) 
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Table 4: Follow-up of patients with atypical idiopathic inflammatory demyelinating lesions (AIIDL) 
 
 AIIDL subtypes 
 
Infiltrative 
(n=34) 
Megacystic 
(n=13) 
Baló-like 
(n=6) 
Ring-like 
 (n=13) 
other 
(n=11) 
Duration of follow-up in years, mean +/- SD   4.2 +/- 2.7 4.8 +/- 3.0 1.8 +/- 1.6 3.0 +/- 1.8 4.8 +/- 3.0 
Clinical           
no further attack, patient number (%) 22 (64.7) 10 (76.9) 4 (66.7) 5 (38.5) 8 (72.7) 
1 attack, patient number (%) 5 (14.7) 2 (15.4) 2 (33.3) 5 (38.5) 0 (0) 
≥2 attacks, patient number (%) 7 (20.6) 1 (7.69) 0 3 (23.0) 3 (27.3) 
EDSS at last follow-up, mean (range) 2.5 (0-7) 2 (1-4) 1.5 (0-2) 3.5 (0-6.5) 2.0 (0-6) 
MRI           
new AIIDLs (same/other type) 1 / 0 0/1 0 1/2 0/1 
new MS-typical lesions (yes/no) 10 / 18 2 / 9 1 /5 9 / 4 7 / 4 
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Table 5: Follow-up results of patients with an without co-existing MS typical lesions  
 
  AIIDL subtypes 
  Infiltrative Megacystic  Baló-like  Ring-like  Others  
      
With coexisting MS typical lesions 19 8 5 10 4 
           
further attacks, n (%) 10 (52.6) 1 (12.5) 1 (16.6) 5 (50.0) 2 (50.0) 
1 attack 3 (15.7) 1 (12.5) 1 (16.6) 3 (30.0) 0 
≥2 attacks 7 (36.8) 0 0 2 (20.0) 2( 50.0) 
new MS-typical lesions on MRI(yes/no) 8/5 1/5 1/4 7/3 3/1 
      
Without coexisting MS typical lesion 15 5 1 3 7 
      
further attacks, n (%)  2 (13.3) 0 0 0 1 (14.3) 
1 attack 1 (6.6) 0 0 0 0 
≥2 attacks 1 (6.6) 0 0 0 1 (14.3) 
new MS-typical lesions on MRI (yes/no) 2/13 1/4 0/1 2/1 4/3 
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Figure Legend 
 
Figure 1: Examples of atypical idiopathic inflammatory demyelinating lesions 
(AIIDLs): a) infiltrative, b) megacystic, c) Baló-like, d) ring-like 
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